Kurs & Likviditet
|2020-10-09||Ordinarie utdelning DEX 0.00 SEK|
|2019-10-11||Ordinarie utdelning DEX 0.00 SEK|
|2019-05-28||Extra Bolagsstämma 2019|
|2018-10-11||Ordinarie utdelning DEX 0.00 SEK|
|2017-11-10||Ordinarie utdelning DEX 0.00 SEK|
|2016-11-04||Ordinarie utdelning DEX 0.00 SEK|
|2016-09-13||Extra Bolagsstämma 2016|
|2015-11-04||Ordinarie utdelning DEX 0.00 SEK|
|2014-11-28||Ordinarie utdelning DEX 0.00 SEK|
On Thursday, October 8, 2020, DexTech Medical AB ("DexTech") will hold its Annual General Meeting. Subject to availability, non-shareholders are also welcome to participate without voting rights. At the meeting, the founders, CEO Anders R Holmberg and medical director Professor Sten Nilsson, will present the company and the current clinical situation regarding prostate cancer. There will be an opportunity to ask questions to DexTech's board and management. Formal notice of the Annual General Meeting is available later in this press release.
Due to the prevailing pandemic, there will be sparse seating with proper distance between those present.
Registration for non-shareholders must be made no later than Tuesday, October 6, 2020 and can be made via e-mail (firstname.lastname@example.org)or in writing to DexTech Medical AB, Annual General Meeting, Box 389, 751 06 Uppsala.
The Annual General Meeting begins at 10.00 in IVA's conference center, Kungl. Academy of Engineering Sciences, Grev Turegatan 16, Stockholm. Admission to the Annual General Meeting begins at 9.30.
Note in addition to the above that participation for non-shareholders presupposes a formal approval from the AGM during the beginning of the AGM.
For additional information:
Gösta Lundgren - CFO & Investor Relations
DexTech Medical AB
Telephone: +46 (0) 707104788
The information was submitted for publication on September 8, 2020, through the contact of the above contact person.
DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with skeletal metastases. A successful Phase II clinical trial has been conducted with OsteoDex where the result shows high tolerability with mild side effects as well as treatment effect on patients who fail on existing drugs. DexTech's goal is to license the respective drug candidate by the latest phase II study. DexTech Medical AB is listed on the Spotlight Stock Market.
See below formal notice of the Annual General Meeting
WELCOME TO THE ANNUAL GENERAL MEETING 2020 IN DEXTECH MEDICAL AB (publ)
Dextech Medical AB's shareholders are welcome to attend the Annual General Meeting that takes place
Thursday, October 8, 2020 at 10.00 in IVA's conference center, Royal. Academy of Engineering Sciences, Grev Turegatan 16, Stockholm.
Admission to the Annual General Meeting begins at 9.30.
Due to prevailing pandemic, there will be sparse seating with proper distance between those present.
Subject to space and that the AGM so decides, non-shareholders are also welcome to participate in the AGM without the right to vote.
Registration and registration
Shareholders who wish to participate in the Annual General Meeting must
- be entered in the share register kept by Euroclear Sweden AB on Wednesday, September 30, 2020 and
- register with the company no later than Tuesday, October 6, 2020. Registration can be made via e-mail (email@example.com)or in writing to Dextech Medical AB, Annual General Meeting, Box 389, 751 06 Uppsala.
The Annual General Meeting will be held in Swedish.
Shareholders who have their shares nominee-registered, through a bank or other nominee, must, in order to be entitled to participate in the Annual General Meeting, temporarily register the shares in their own name with Euroclear Sweden AB. Such re-registration must be completed no later than Wednesday, September 30, 2020, which means that shareholders who wish such re-registration must notify the nominee of this well in advance of the said date.
If shareholders are to be represented by a proxy, the proxy must have a written, dated and signed proxy for the meeting by the shareholder. The power of attorney may not be older than one year, unless a longer period of validity (however, a maximum of five years) has been stated on the power of attorney. If the power of attorney has been issued by a legal entity, the representative must also have the relevant registration certificate or equivalent authorization documents for the legal entity. To facilitate entry, a copy of the power of attorney and other authorization documents should be attached to the notification to the meeting. Proxy forms are kept available on the company's website www.dextechmedical.com and are sent by post to shareholders who contact the company and state their address.
1. Election of chairman of the meeting.
2. Establishment and approval of the ballot paper.
3. Approval for non-shareholders to attend the meeting.
4. Approval of agenda.
5. Election of one or two adjusters.
6. Examination of whether the meeting has been duly convened.
7. CEO's speech and a presentation of the clinical situation by Professor Sten Nilsson as well as questions from the shareholders to the company's board and management.
8. Presentation of the annual report and auditor's report for the financial year 2019/2020.
9. Decision on adoption of the income statement and balance sheet.
10. Resolution on dispositions regarding the company's profit or loss according to the approved balance sheet.
11. Resolution on discharge from liability for the members of the Board of Directors and the President.
12. Determination of the number of board members, deputy board members and, where applicable, of the number of auditors or audit firms and any deputy auditors.
13. Determination of fees to the Board and the auditors.
14. Election of the board and any deputy board members.
15. Election of auditors or audit firms and any deputy auditors.
16. Other matters, which come to the meeting in accordance with the Swedish Companies Act or the Articles of Association.
17. Closing of the Meeting.
Decision proposal in brief
Determination of the number of board members and deputy board members (item 12)
According to the Articles of Association, the Board shall consist of a minimum of three and a maximum of seven members with a maximum of two deputies. Shareholders representing just over 60 percent of the total number of shares in the company have proposed that the number of board members be unchanged at five members and that no deputies be elected.
Determination of fees to the Board and the auditors (item 13)
Shareholders representing just over 60% of the total number of shares in the company have proposed that board fees shall not be paid and that fees to the auditor shall be paid according to an approved invoice.
Election of board (item 14)
Shareholders representing just over 60% of the total number of shares in the company have proposed that the following persons be elected as board members:
Re-election of Svante Wadman, Anders Holmberg, Sten Nilsson, Per-Olof Asplund and Rolf Eriksson.
Election of auditor (item 15)
Shareholders representing just over 60% of the total number of shares in the company have proposed re-election of KPMG AB as auditor.
The Board's proposal
Disposition of the Company's earnings (item 10)
The funds available to the Annual General Meeting consist of the result for the year of - SEK 7,713,785, the company's share premium fund of SEK 68,224,318 and the Company's retained earnings of - SEK 55,060,239, a total of SEK 5,450,294.
The Board of Directors proposes that the funds available to the Annual General Meeting of SEK 5,450,294 be transferred to a new account.
Shares and votes
The company has a total of 14,920,478 shares and the same number of votes.
The annual report and auditor's report are available on the company's website www.dextechmedical.com.
Stockholm in September 2020
THE BOARD OF DIRECTORS